Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.
Cellular therapy of Epstein-Barr virus (EBV)(+) posttransplantation lymphoproliferative diseases (PTLD) in cord blood transplant (CBT) recipients is limited by lack of donor access and the donor's naive neonatal immune system. We therefore used partially human leukocyte antigen-matched third-party in vitro expanded EBV-specific cytotoxic T lymphocytes (CTLs) to treat 2 CBT recipients with life-threatening, donor-derived monoclonal EBV(+) diffuse large B-cell lymphomas with extranodal involvement developing in the context of graft-versus-host disease. Both patients had failed immunosuppression taper and Rituximab. After 5 and 9 infusions of 10(6) EBV-CTL/kg, respectively, each patient achieved a sustained complete remission without toxicity or graft-versus-host disease. Each is alive without recurrence at 20 and 15 months, respectively, post-EBV-PTLD diagnosis. This approach demonstrates the efficacy of using "off-the-shelf," virus-specific third-party CTLs restricted by human leukocyte antigens expressed by the tumor to treat otherwise lethal EBV-PTLD. Such therapy may also be applicable to the treatment of other infections and residual or recurrent malignancy after CBT.
Barker
Juliet N
JN
Department of Medicine, Allogeneic Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. barkerj@mskcc.org
Doubrovina
Ekaterina
E
Sauter
Craig
C
Jaroscak
Jennifer J
JJ
Perales
Miguel A
MA
Doubrovin
Mikhail
M
Prockop
Susan E
SE
Koehne
Guenther
G
O'Reilly
Richard J
RJ
D000328:Adult; D002648:Child; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects*; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000628:therapy; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000601:surgery; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy* / Q000821:virology; D008297:Male; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*
D006680:HLA Antigens
Lancet. 2002 Aug 10;360(9331):436-42
12241714
Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91
19835968
Immunol Res. 2007;38(1-3):237-50
17917029
Blood. 2002 Mar 1;99(5):1730-40
11861290
Blood. 2009 Aug 27;114(9):1958-67
19443656
Blood. 2006 Apr 15;107(8):3053-7
16254143
Blood. 2007 Aug 15;110(4):1123-31
17468341
Blood. 2006 Sep 1;108(5):1770-3
16675712
Blood. 2006 Oct 15;108(8):2874-80
16804113
Blood. 2000 Jul 1;96(1):109-17
10891438
Blood. 2010 Feb 4;115(5):925-35
19880495
Bone Marrow Transplant. 2006 Mar;37(6):539-46
16462755
Cell Immunol. 1999 Aug 1;195(2):81-8
10448007
Biol Blood Marrow Transplant. 2001;7(7):395-9
11529490
Blood. 2009 Nov 5;114(19):4002-8
19724053